Nordea Investment Management AB Has $124.15 Million Stake in Illumina, Inc. $ILMN

Nordea Investment Management AB grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 2,792.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 944,500 shares of the life sciences company’s stock after buying an additional 911,843 shares during the period. Nordea Investment Management AB owned approximately 0.62% of Illumina worth $124,145,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Board of the Pension Protection Fund acquired a new position in shares of Illumina in the 4th quarter valued at $26,000. Quent Capital LLC bought a new position in Illumina during the 3rd quarter worth about $29,000. Quarry LP acquired a new stake in shares of Illumina in the 3rd quarter valued at about $32,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Illumina in the 3rd quarter valued at about $33,000. Finally, Strategic Advocates LLC bought a new stake in shares of Illumina in the third quarter valued at about $44,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ILMN. Guggenheim increased their price objective on Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Wall Street Zen upgraded Illumina from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 14th. Piper Sandler reduced their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research report on Monday, February 9th. UBS Group reaffirmed a “neutral” rating and set a $135.00 price target on shares of Illumina in a research note on Friday, February 6th. Finally, TD Cowen reiterated a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Six analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $129.69.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $124.33 on Monday. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. The business has a 50-day moving average of $130.92 and a 200-day moving average of $120.95. The stock has a market capitalization of $19.01 billion, a price-to-earnings ratio of 22.81, a PEG ratio of 2.38 and a beta of 1.45. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $155.53.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the prior year, the company posted $0.95 earnings per share. Illumina’s revenue was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the transaction, the senior vice president directly owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.17% of the stock is currently owned by company insiders.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.